VH
Therapeutic Areas
AN2 Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AN2-502998 (oral) | Chagas Disease | Phase 2/3 |
| Epetraborole | Melioidosis | Phase 2/3 |
| Boron-based compounds | NTM Lung Disease (M. abscessus) | Preclinical |
Leadership Team at AN2 Therapeutics
EE
Eric Easom
Co-Founder, President & CEO, Chair of the Board of Directors
MR
Michael R.K. (Dickon) Alley, Ph.D.
SVP Research Fellow, Head of Biology
SC
Sanjay Chanda, Ph.D.
Chief Development Officer
LO
Lucy O. Day
Chief Financial Officer
JE
Josh Eizen
Chief Legal Officer and Chief Operating Officer